Literature DB >> 22936283

Physicochemical interactions in solid dosage forms.

Ajit S Narang, Divyakant Desai, Sherif Badawy.   

Abstract

Complete characterization and mechanistic understanding of physicochemical interactions in solid dosage forms are not only important for consistent manufacturability, stability, and bioavailability of the drug product, but are also expected under the quality-by-design paradigm of drug development. Lack of this understanding can impact successful and timely development, scale-up, and commercial manufacture of dosage forms. This article highlights the stability and bioavailability implications of physicochemical interactions in dosage forms citing a couple of examples where such interactions necessitated the recall of commercial drug products.

Mesh:

Substances:

Year:  2012        PMID: 22936283     DOI: 10.1007/s11095-012-0867-5

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  4 in total

Review 1.  Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility.

Authors:  Yongmei Wu; Jaquan Levons; Ajit S Narang; Krishnaswamy Raghavan; Venkatramana M Rao
Journal:  AAPS PharmSciTech       Date:  2011-09-27       Impact factor: 3.246

2.  Reversible and pH-dependent weak drug-excipient binding does not affect oral bioavailability of high dose drugs.

Authors:  Ajit S Narang; Aaron P Yamniuk; Limin Zhang; S Nilgun Comezoglu; Dilbir S Bindra; Sailesh Varia; Michael L Doyle; Sherif Badawy
Journal:  J Pharm Pharmacol       Date:  2012-01-13       Impact factor: 3.765

3.  Ritonavir: an extraordinary example of conformational polymorphism.

Authors:  J Bauer; S Spanton; R Henry; J Quick; W Dziki; W Porter; J Morris
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

4.  What happened: the chemistry side of the incident with EMS contamination in Viracept tablets.

Authors:  Christoph Gerber; Heinz-Gerhard Toelle
Journal:  Toxicol Lett       Date:  2009-03-09       Impact factor: 4.372

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.